secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2024-01-30T23:59:59+00:00
Accession:  0001683168-24-000540
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma appoints new COO and Chief Development Officer at annual meeting
--------------------------------------------------------------------------------

- Marc Beaudoin appointed COO; Malek Chamoun appointed Chief Development Officer, effective Jan 25, 2024.
- Dr. Abderrazzak Merzouki moved from COO to Chief Science Officer.
- Camille Sebaaly continues as CFO/Secretary; Dr. Steve Slilaty continues as President/CEO.
- Malek Chamoun is also President of subsidiary Nora Pharma Inc., acquired in Oct 2022.
- Beaudoin has 10 years at Sandoz Canada; Chamoun is a CPA with HEC Montreal degree.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824000540/0001683168-24-000540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824000540/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-000540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer